Evogene (Israel) Top Management
| EVGN Stock | ILA 241.10 15.70 6.11% |
Evogene employs about 133 people. The company is managed by 36 executives with a total tenure of roughly 298 years, averaging almost 8.0 years of service per executive, having 3.69 employees per reported executive. Analysis of Evogene's management performance can provide insight into the company performance.
| Ofer Haviv CEO President, Chief Executive Officer |
| Martin Gerstel Chairman Chairman of the Board |
Evogene |
Evogene Management Team Effectiveness
The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.Evogene Workforce Comparison
Evogene is one of the top stocks in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 5,681. Evogene holds roughly 133 in number of employees claiming about 2.34% of equities under Health Care industry.
Evogene Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Evogene Price Series Summation is a cross summation of Evogene price series and its benchmark/peer.
Evogene Notable Stakeholders
An Evogene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evogene often face trade-offs trying to please all of them. Evogene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evogene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ofer Haviv | President, Chief Executive Officer | Profile | |
| Martin Gerstel | Chairman of the Board | Profile | |
| Mark Kapel | Executive Vice President-Technology | Profile | |
| Eran Kosover | Executive Vice President & General Manager Ag-Chemicals | Profile | |
| Amos Shachar | Vice President of Project Management | Profile | |
| Ido Dor | Executive Vice President & General Manager Ag-Biologicals | Profile | |
| Alin SelaBrown | Vice President Screening & Validation Systems | Profile | |
| Eyal Emmanuel | Executive Vice President-R&D | Profile | |
| Arnon Heyman | Vice President & General Manager of Ag-Seeds | Profile | |
| Eyal Leibovitz | CFO | Profile | |
| Alex Taskar | Chief Financial Officer | Profile | |
| Yuval BenGalim | COO | Profile | |
| Hagai Karchi | Chief Technology Officer & Head of R&D Ag-Biologicals | Profile | |
| Assaf Oron | Executive VP Corporate Devel. | Profile | |
| Oded Shoseyov | Director | Profile | |
| Adina Makover | Independent Director | Profile | |
| Adrian Percy | Director | Profile | |
| Sarit Firon | Independent Director | Profile | |
| Michael Anghel | External Director | Profile | |
| Leon Recanati | Independent Director | Profile | |
| Kinneret Savitsky | Independent Director | Profile | |
| Eli Zangvil | Director | Profile | |
| Kinneret Savitzky | External Director | Profile | |
| Simcha Sadan | Director | Profile | |
| Lea Bloom | Director of Administration & Human Resources | Profile | |
| Ziv Kop | Independent Director | Profile | |
| Yaron Eldad | Chief Officer | Profile | |
| Eyal Ronen | Exec Devel | Profile | |
| Sassi Masliah | Exec Devel | Profile | |
| Liat Wejgman | VP HR | Profile | |
| Ofer CPA | CEO Pres | Profile | |
| Sigal Fattal | Executive Officer | Profile | |
| Dotan Borenstein | Chief Ltd | Profile | |
| Nir Arbel | Chief Officer | Profile | |
| Assaf Kacen | Chief Operation Officer | Profile | |
| Elran MBA | Chief Ltd | Profile |
About Evogene Management Performance
The success or failure of an entity such as Evogene often depends on how effective the management is. Evogene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evogene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evogene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.
The data published in Evogene's official financial statements usually reflect Evogene's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Evogene. For example, before you start analyzing numbers published by Evogene accountants, it's critical to develop an understanding of what Evogene's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Evogene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Evogene's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Evogene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evogene. Please utilize our Beneish M Score to check the likelihood of Evogene's management manipulating its earnings.
Evogene Workforce Analysis
Traditionally, organizations such as Evogene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evogene within its industry.Evogene Manpower Efficiency
Return on Evogene Manpower
| Revenue Per Employee | 7K | |
| Revenue Per Executive | 25.8K | |
| Net Loss Per Employee | 209K | |
| Net Loss Per Executive | 772K | |
| Working Capital Per Employee | 669.2K | |
| Working Capital Per Executive | 2.5M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |